Exclusive: 'Faster isn't better' — Atomwise moves from partnerships to pipeline with TYK2 drug
Atomwise, one of the first startups to start pitching an AI revolution in drug discovery just over a decade ago is now taking a page from the traditional biotech playbook.
The San Francisco biotech is shifting its focus from inking hundreds of partnerships that use its AI technology to developing its own pipeline, starting with a TYK2 drug. Atomwise has hired Neely Mozaffarian as its chief medical officer, CEO Abraham Heifets told Endpoints News in an exclusive interview on his company’s future. Mozaffarian is an industry veteran of GentiBio, Johnson & Johnson, and Gilead Sciences.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.